摘要
目的观察卡维地洛对慢性心力衰竭(心衰)患者神经激素及镁代谢的影响。方法57例心衰患者随机分为2组,分别在常规治疗基础上合用卡维地洛或谷维素治疗8周,治疗前后测定血浆去甲肾上腺素、肾素(PRA)、血管紧张素-Ⅱ(ANG-Ⅱ)、醛固酮(ALD)、血浆镁浓度(PMC)、外周血单核细胞镁含量(MMC)及24H尿镁排泄量(UME),并选择26例健康者为正常对照。结果与正常对照组比较,心衰患者血浆去甲肾上腺素、PRA、ANG-Ⅱ、ALD及尿UME均明显升高,MMC降低(P<0·01),UME分别与ALD、ANG-Ⅱ、PRA呈正相关(R=0·41、0·42、0·38,P<0·01)。卡维地洛治疗后,血浆ALD、PRA、ANG-Ⅱ及尿UME降低(P<0·05),MMC增加(P<0·01)。结论卡维地洛阻断神经激素激活,同时减少尿镁排泄,增加细胞内镁水平。
Objective To investigate the effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure （CHF）. Methods Fifty-seven patients with CHF were divided into two groups randomly： received conventional treatment alone or combined with carvedilol for 8 weeks, respectively. Urine magnesium excretion （ UME ）, plasma levels of magnesium （ PMC ）, norepinephrine （ NE）, angiotensin- Ⅱ （ Ang- Ⅱ ）, aldosterone （ ALD ）, plasma renin activity （ PRA ） and peripheral monocyte magnesium content （MMC） were measured before and after treatments. Twenty-six health persons were selected as normal subjects. Results There was a significant increase in UME and plasma concentrations of NE, ALD, Ang- Ⅱ and PRA, and a significant decrease in MMC in patients with CHF,compared with the control group （P 〈 0. 01 ）. UME was positively correlated with ALD, Ang-Ⅱ, PRA, r = 0.41,0.42,0.38, respectively （P 〈0.01）. These parameters significantly improved after carvedilol （P 〈 0. 05 ）. Conclusion Carvedilol decreases significantly plasma concentrations of neurohormon and urine magnesium excretion, and increases cell magnesium content in patients with CHF.
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
2005年第11期995-997,共3页
Chinese Journal of Cardiology
